• Phone935813076, 935811573
  • Edifici M planta 1ª torre M1

    08193 Bellaterra (Cerdanyola del Vallès)


  • Edif. M, Avd. de Can Domènech

    08193 Bellaterra (Cerdanyola del Vallès)

Accepting PhD Students

  • Source: Scopus
  • Calculated based on no. of publications stored in Pure and citations from Scopus
1990 …2022

Research activity per year

If you made any changes in Pure these will be visible here soon.

Personal profile

Research interests

Lizcano’s Lab is interested in dissecting new cellular signaling pathways that control cancer cell proliferation and differentiation.  We collaborate with academics and Biopharma Companies to perform preclinical development of new anticancer drugs. Specifically, we are interested in deciphering the role of the new MAP kinase ERK5 (a MAP kinase) in cancer proliferation and survival. We are also interested in modulation of autophagy and endoplasmic reticulum (ER) stress as new strategies to tackle cancer

We use two different perspectives to approach fundamental problems:

a) Basic Research. Dissection of the mechanisms by ERK5 kinase (as well other kinases) exert a control on the proliferation and survival of tumor cells. We have contributed to propose new molecular mechanism for regulation of protein kinase Akt; discovered that tumor suppressor kinase LKB1 functions as a master kinase; or more recently, we have established a new mechanism by which ERK5 translocates to the nucleus and regulates the proliferation of tumor cells regardless of its enzymatic activity.

b) Research directed to pharmacological intervention in cancer. We are involved in potentiating translational aspects of our resources. We actively collaborate with Ability Pharmaceuticals SL in the preclinical/clinical development of the new antitumor drug ABTL0812, which it is Clinical Trial Phase II to treat cancer patients with advanced endometrial and squamous NSCLC cancers (NCT02201823). We have discovered a new cellular signaling pathway by which ABTL0812 exerts its antitumor action: by altering the sphingolipidoma of cancer cells, ABTL0812 induces a sustained activation of ER stress and UPR, as well as inhibition of the Akt/mTORC1, which ultimately results in activation of cytotoxic autophagy. Finally, we actively collaborate with other academic laboratories characterizing new ERK5 inhibitors with anticancer activity.


1) Role of MAP kinase ERK5 in cancer cell proliferation and survival (neuroblastoma and endometrial cancer)

2) Preclinical development of new drugs for cancer therapy. Antitumoral drugs that exert their action by activating cytotoxic autophagy. New ERK5 inhibitors with anti-cancer activity.

Expertise related to UN Sustainable Development Goals

In 2015, UN member states agreed to 17 global Sustainable Development Goals (SDGs) to end poverty, protect the planet and ensure prosperity for all. This person’s work contributes towards the following SDG(s):

  • SDG 3 - Good Health and Well-being

Education/Academic qualification

Ph. D., Universitat Autònoma de Barcelona (UAB)

Award Date: 20 Dec 1994

Masters, Universitat Autònoma de Barcelona (UAB)

Award Date: 20 Sep 1989

Degree, Universitat Autònoma de Barcelona (UAB)

Award Date: 1 Jul 1987

External positions

MRC Research Associate, MRC Protein Phosphorylation Unit, University of Dundee (UK)

1 Nov 200031 Aug 2004

Post-doctoral researcher, Department of Biochemistry, Trinty College Dublin (Ireland)

1 Jul 199530 Mar 1996

Professor ajudant de Facultat (2na etapa), Dept Bioquimica, Facultad de Medicina

12 Jan 199514 Sep 1998

Prof. ayudante de Facultad (1ª etapa), Universitat Autònoma de Barcelona (UAB)

1 Feb 199211 Jan 1995

Prof. ayudante de escuela Univ., Dept Bioquimica, Facultad de Medicina

1 Sep 19911 Feb 1992


Dive into the research topics where Jose Miguel Lizcano de Vega is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
  • 1 Similar Profiles


Recent external collaboration on country/territory level. Dive into details by clicking on the dots or